Claire Hara-Cleaver

577 total citations
11 papers, 436 citations indexed

About

Claire Hara-Cleaver is a scholar working on Pathology and Forensic Medicine, Rheumatology and Molecular Biology. According to data from OpenAlex, Claire Hara-Cleaver has authored 11 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 5 papers in Rheumatology and 3 papers in Molecular Biology. Recurrent topics in Claire Hara-Cleaver's work include Multiple Sclerosis Research Studies (9 papers), Systemic Lupus Erythematosus Research (3 papers) and Autoimmune and Inflammatory Disorders Research (3 papers). Claire Hara-Cleaver is often cited by papers focused on Multiple Sclerosis Research Studies (9 papers), Systemic Lupus Erythematosus Research (3 papers) and Autoimmune and Inflammatory Disorders Research (3 papers). Claire Hara-Cleaver collaborates with scholars based in United States and Canada. Claire Hara-Cleaver's co-authors include Richard A. Rudick, Ruth Ann Marrie, Robert Bermel, Jeffrey A. Cohen, Daniel Ontaneda, Carrie M. Hersh, Elizabeth Fisher, Robert J. Fox, Jar-Chi Lee and Stephen E. Jones and has published in prestigious journals such as Neurology, Journal of the Neurological Sciences and JAMA Neurology.

In The Last Decade

Claire Hara-Cleaver

11 papers receiving 427 citations

Peers

Claire Hara-Cleaver

PFM

ONCOL

NEURO

RHEUM

Jonathan Hosey United States

Michael Haboubi Canada

Hanna Kuusisto Finland

Victoria Fernández Spain

Aurora Fuiani Italy

Magd Zakaria Egypt

DS Goodin United States

B. Runmarker Sweden

Zoé L. E. van Kempen Netherlands

В. Л. Филиппов Switzerland

Jonathan Hosey United States

Claire Hara-Cleaver

433 ×1.2

PFM

121 ×1.2

ONCOL

127 ×1.3

NEURO

43 ×0.5

89 ×1.1

RHEUM

Citations per year, relative to Claire Hara-Cleaver Claire Hara-Cleaver (= 1×) peers Jonathan Hosey

Countries citing papers authored by Claire Hara-Cleaver

Since Specialization

Citations

This map shows the geographic impact of Claire Hara-Cleaver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claire Hara-Cleaver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claire Hara-Cleaver more than expected).

Fields of papers citing papers by Claire Hara-Cleaver

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claire Hara-Cleaver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claire Hara-Cleaver. The network helps show where Claire Hara-Cleaver may publish in the future.

Co-authorship network of co-authors of Claire Hara-Cleaver

This figure shows the co-authorship network connecting the top 25 collaborators of Claire Hara-Cleaver. A scholar is included among the top collaborators of Claire Hara-Cleaver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claire Hara-Cleaver. Claire Hara-Cleaver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Nakamura, Kunio, et al.. (2024). Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial. Multiple Sclerosis Journal. 30(6). 687–695. 5 indexed citations

Hersh, Carrie M., Thomas E. Love, Claire Hara-Cleaver, et al.. (2017). Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Multiple Sclerosis Journal - Experimental Translational and Clinical. 3(3). 2452135453–2452135453. 36 indexed citations

Hersh, Carrie M., Claire Hara-Cleaver, Robert J. Fox, et al.. (2017). Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up (S31.003). Neurology. 88(16_supplement). 2 indexed citations

Hersh, Carrie M., Thomas E. Love, Claire Hara-Cleaver, et al.. (2016). Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Multiple Sclerosis and Related Disorders. 10. 44–52. 46 indexed citations

Hersh, Carrie M., Claire Hara-Cleaver, Richard A. Rudick, et al.. (2014). Experience with fingolimod in clinical practice. International Journal of Neuroscience. 125(9). 678–685. 31 indexed citations

Fisher, Elizabeth, et al.. (2012). Reliability of Classifying Multiple Sclerosis Disease Activity Using Magnetic Resonance Imaging in a Multiple Sclerosis Clinic. JAMA Neurology. 70(3). 338–338. 67 indexed citations

Ontaneda, Daniel, Claire Hara-Cleaver, Richard A. Rudick, Jeffrey A. Cohen, & Robert Bermel. (2012). Early tolerability and safety of fingolimod in clinical practice. Journal of the Neurological Sciences. 323(1-2). 167–172. 41 indexed citations

Rudick, Richard A., et al.. (2012). Inter-Rater Reliability among Clinical Raters for New MRI Lesions in MS Patients (P03.068). Neurology. 78(Meeting Abstracts 1). P03.068–P03.068. 1 indexed citations

Rudick, Richard A., et al.. (2010). Validation of a Self-Report Comorbidity Questionnaire for Multiple Sclerosis. Neuroepidemiology. 35(2). 83–90. 131 indexed citations

10.

Cohen, J. A., Peter B. Imrey, Peter A. Calabresi, et al.. (2009). Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 72(6). 535–541. 56 indexed citations

11.

Cohen, JA, Peter A. Calabresi, Elizabeth Fisher, et al.. (2008). Avonex Combination Trial in relapsing—remitting MS: rationale, design and baseline data. Multiple Sclerosis Journal. 14(3). 370–382. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact